Chemo-Light trio shows promise for elderly lymphoma patients
NCT ID NCT05798156
First seen Apr 08, 2026 · Last updated May 23, 2026 · Updated 9 times
Summary
This phase 2 study tests a new drug combination (rituximab, polatuzumab vedotin, and glofitamab) that uses less chemotherapy than standard treatment. It is designed for people over 60 with aggressive B-cell lymphoma who cannot tolerate full-dose chemo. The goal is to see if this lighter approach can control the disease and improve survival without the harsh side effects of traditional chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AKH Meduni Wien
Vienna, Austria
-
Charité - Universitätsmedizin Berlin
Berlin, Germany
-
Ev. Klinikum Essen-Mitte
Essen, Germany
-
HELIOS Klinikum Berlin-Buch
Berlin, Germany
-
Hanusch Krankenhaus
Vienna, Austria
-
Kepler Universitätsklinikum
Linz, Austria
-
Klinikum Chemnitz
Chemnitz, Germany
-
Klinikum Ludwigshafen
Ludwigshafen, 67063, Germany
-
Kreiskliniken Reutlingen
Reutlingen, Germany
-
Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
Salzburg, Austria
-
Medizinisches Universitätsklinikum Knappschaftskrankenhaus Bochum
Bochum, Germany
-
Ordensklinikum Linz - Barmherzige Schwestern
Linz, Austria
-
Ordensklinikum Linz - Elisabethinen
Linz, Austria
-
Ortenauklinikum Offenburg-Kehl
Offenburg, Germany
-
TU München (rechts des Isar)
München, Germany
-
Uniklinik Innsbruck
Innsbruck, Austria
-
Uniklinikum Düsseldorf
Düsseldorf, Germany
-
Univ. Klinikum St. Pölten
Sankt Pölten, Austria
-
University Hospital Jena
Jena, Germany
-
Universitätsklinikum Erlangen
Erlangen, Germany
-
Universitätsklinikum Halle
Halle, Germany
-
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
-
Universitätsklinikum Magdeburg
Magdeburg, Saxony-Anhalt, 39120, Germany
-
Universitätsklinikum Regensburg
Regensburg, Germany
-
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, Germany
-
Universitätsklinikum Würzburg
Würzburg, Germany
-
Unversitätsklinikum Münster
Münster, 48149, Germany
-
Westdeutsches Tumorzentrum Essen
Essen, Germany
Conditions
Explore the condition pages connected to this study.